Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

(Reuters) -Eli Lilly raised its full-year profit forecast on Thursday, betting on surging demand for its blockbuster ...

Zepbound functions by targeting hormone receptors related to appetite regulation, specifically glucagon-like peptide-1 and ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...